Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
作者： D Fennelly , C Aghajanian , F Shapiro , C O'Flaherty , M McKenzie
DOI: 10.1200/JCO.1997.15.1.187
关键词:
摘要: PURPOSEPaclitaxel has shown significant activity in advanced ovarian cancer. In vitro studies with paclitaxel have suggested that fractionated brief infusion schedules may be more effective than the standard 24-hour infusion. We commenced a phase I evaluation of escalating-dose (40, 50, 60, 80, 100 mg/m2) administered weekly as 1-hour patients recurrent All had received prior and cisplatin therapy. premedication.PATIENTS AND METHODSEighteen are assessable on this study. The mean age was 54 years (range, 48 to 74). median number chemotherapy regimens three two five). paclitaxel-free interval 10.1 months 1 24).RESULTSA total 194 cycles therapy were administered, 10 one 12) per patient. No mucositis or grade III neuropathy seen. Alopecia occurred out 18 patients. neutrophil nadir ...
utsystem.edu参考文章(13)
M J Glantz, H Choy, C M Kearns, B F Cole, P Mills, E G Zuhowski, S Saris, C H Rhodes, E Stopa, M J Egorin, Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. Journal of Clinical Oncology. ,vol. 14, pp. 600- 609 ,(1996) , 10.1200/JCO.1996.14.2.600
William P. McGuire, Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms Annals of Internal Medicine. ,vol. 111, pp. 273- 279 ,(1989) , 10.7326/0003-4819-111-4-273
U. Klaassen, H. Wilke, D. Strumberg, W. Eberhardt, M. Korn, S. Seeber, Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer European Journal of Cancer. ,vol. 32, pp. 547- 549 ,(1996) , 10.1016/0959-8049(95)00641-9
Lloyd R. Kelland, George Abel, Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemotherapy and Pharmacology. ,vol. 30, pp. 444- 450 ,(1992) , 10.1007/BF00685595
Narima M. Lopes, Earl G. Adams, Thomas W. Pitts, Bijoy K. Bhuyan, Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemotherapy and Pharmacology. ,vol. 32, pp. 235- 242 ,(1993) , 10.1007/BF00685842
M.E. Gore, I. Fryatt, E. Wiltshaw, T. Dawson, Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecologic Oncology. ,vol. 36, pp. 207- 211 ,(1990) , 10.1016/0090-8258(90)90174-J
JE Liebmann, JA Cook, C Lipschultz, D Teague, J Fisher, JB Mitchell, Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. British Journal of Cancer. ,vol. 68, pp. 1104- 1109 ,(1993) , 10.1038/BJC.1993.488
M Markman, R Rothman, T Hakes, B Reichman, W Hoskins, S Rubin, W Jones, L Almadrones, J L Lewis, Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Journal of Clinical Oncology. ,vol. 9, pp. 389- 393 ,(1991) , 10.1200/JCO.1991.9.3.389
Richard B. Lipton, Edward L. Schwartz, Janice P. Dutcher, Janice J. Strauman, Elisabeth Paietta, Peter H. Wiernik, Phase I clinical and pharmacokinetic study of taxol Cancer Research. ,vol. 47, pp. 2486- 2493 ,(1987)
T Brown, K Havlin, G Weiss, J Cagnola, J Koeller, J Kuhn, J Rizzo, J Craig, J Phillips, D Von Hoff, A phase I trial of taxol given by a 6-hour intravenous infusion. Journal of Clinical Oncology. ,vol. 9, pp. 1261- 1267 ,(1991) , 10.1200/JCO.1991.9.7.1261